SHH · 600276.SS
Jiangsu Hengrui Medicine Co., Ltd.
CN¥48.46-CN¥0.16 (-0.33%)
Jiangsu Hengrui Medicine Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 26.39% below the high.
Loading market information…
SHZ · 002294.SZ · CNY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 07:04 AM UTC. Cached market data; not a live quote.
One-year closing-price history · CNY. Historical prices are not a forecast.
Shenzhen Salubris Pharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 57.9% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Shenzhen Salubris Pharmaceuticals Co., Ltd.’s forward annual dividend is CN¥0.55 per share, paid annual. The forward yield is 1.84% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Shenzhen Salubris Pharmaceuticals Co., Ltd.’s next earnings report is currently expected on Mar 30, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Shenzhen Salubris Pharmaceuticals Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily focuses on critical therapeutic areas within China, including cardiovascular, anti-diabetic, anti-cancer, and orthopedic medicine. Its diverse product portfolio features a variety of cardiovascular and cerebrovascular medications, such as allisartan isoproxil and clopidogrel bisulfate tablets, alongside injectable options like bivalirudin. A significant offering is the recombinant SeV-hFGF2/dF Injection, specifically developed for the treatment of diabetic foot disease. Salubris also manufactures anti-tumor and orthopedic drugs. Furthermore, its anti-infective range encompasses numerous injectable antibiotics, including ceftazidime and ceftriaxone sodium, as well as oral preparations such as azithromycin dispersible and levetiracetam tablets. The firm also innovates in biotechnological drugs, developing recombinant proteins and monoclonal antibodies. Complementing its domestic operations, Shenzhen Salubris Pharmaceuticals engages in the import, in-licensing, and out-licensing of medicines, particularly for European markets.
Latest available per-share figures in CNY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:11 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2025 |
|---|
| Apr 21, 2025 |
| CN¥0.180.0% vs estimate |
| CN¥1.06B |
| Q4 2024 | Mar 28, 2025 | CN¥0.08-42.86% vs estimate | CN¥1.01B |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥48.46-CN¥0.16 (-0.33%)
Jiangsu Hengrui Medicine Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 26.39% below the high.
CN¥26.62+CN¥0.74 (+2.86%)
Huadong Medicine Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 39.2% below the high.
CN¥25.28+CN¥0.37 (+1.49%)
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 17.52% below the high.
CN¥28.52+CN¥0.88 (+3.18%)
Livzon Pharmaceutical Group Inc.’s quoted price sits in the lower half of its reported 52-week range, 24.65% below the high.
CN¥19.37-CN¥0.13 (-0.67%)
Apeloa Pharmaceutical Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 32.04% below the high.
CN¥11.65-CN¥0.14 (-1.19%)
Beijing Aosaikang Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 42.21% below the high.
CN¥19.86-CN¥0.29 (-1.44%)
Shenzhen Chipscreen Biosciences Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 45.54% below the high.
CN¥31.73-CN¥0.82 (-2.52%)
Nanjing Hicin Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 56.77% below the high.
